Colorectal cancer is the second most common cancer in women and the third most common in men worldwide. In this study, we used MEDLINE to conduct a systematic review of existing literature published in English between 2000 and 2010 on patterns of colorectal cancer care. Specifically, this review examined 66 studies conducted in Europe, Australia, and New Zealand to assess patterns of initial care, post-diagnostic surveillance, and end-of-life care for colorectal cancer. The majority of studies in this review reported rates of initial care, and limited research examined either post-diagnostic surveillance or end-of-life care for colorectal cancer. Older colorectal cancer patients and individuals with comorbidities generally received less surgery, chemotherapy, or radiotherapy. Patients with lower socioeconomic status were less likely to receive treatment, and variations in patterns of care were observed by patient demographic and clinical characteristics, geographical location, and hospital setting. However, there was wide variability in data collection and measures, health-care systems, patient populations, and population representativeness, making direct comparisons challenging. Future research and policy efforts should emphasize increased comparability of data systems, promote data standardization, and encourage collaboration between and within European cancer registries and administrative databases.
In 2008, an estimated 2.1 million individuals were diagnosed with colorectal cancer worldwide, with nearly 60% residing in developed regions (1, 2) . Globally, colorectal cancer is the second most common cancer in women and third in men (1, 2) . Although rates vary significantly by regions of the world, Australia/New Zealand and Western Europe have among the highest estimated incidence rates of colorectal cancer (1, 2) . For both genders, Central and Eastern Europe have the highest mortality rates because of colorectal cancer worldwide (1, 2) . Given that the likelihood of developing colorectal cancer increases with older age, global prevalence is rising over time because of growing proportions of elderly (1, 2) . Better methods of screening and early detection and advances in treatment are also improving survival, further contributing to increasing prevalence (1, 2) . Undoubtedly, these increases have significant implications for health-care costs, delivery, and service utilization associated with this disease.
Given high rates of mortality and incidence for colorectal cancer in certain parts of Europe, this region of the world is an important area of international focus. Available comparative research on cancer in European countries has primarily come from studies conducted by EUROCARE, a research collaboration between several European population-based cancer registries that began in 1990 (3) . EUROCARE was designed to develop standardized measures for improved comparability of cancer data between European countries and explore trends in patterns of cancer treatment and survival (3) . Findings from these studies have demonstrated considerable variation in age-adjusted 5-year survival by country and region, with the highest colorectal cancer survival rates in northern European countries and the lowest in Eastern European countries (4-9).
A study comparing colorectal cancer survival in Europe to the United States during the period of 1985-1989 found that 5-year survival ranged from 13% to 22% higher in the United States depending upon tumor subsite (10) . Verdecchia et al. compared data from 47 European registries to data from Surveillance, Epidemiology, and End Results (SEER) and noted higher mean survival in the United States compared with Europe for multiple cancers, including colorectal cancer, for patients diagnosed in 1995-1999 and followed up to December 2003 (7) . Although limited, existing studies have suggested that differences in stage at diagnosis, postoperative mortality, and access to care may be factors that partially explain variations in outcomes between European nations (11) (12) (13) .
With the larger goal of improving delivery of population-based care for colorectal cancer, assessment of current practices is a necessary first step. Therefore, we conducted this systematic review of published studies to evaluate patterns of initial care following diagnosis, post-diagnostic surveillance, and end-of-life care for colorectal cancer in Europe, Australia, and New Zealand. Examination of this literature will provide a deeper understanding of care patterns and trends over time and may identify disparities in treatment. Assessment of data comparability between nations can also inform data collection and in combination with patient outcomes and cost data, assist resource allocation, health-care delivery, and research and policy efforts targeting colorectal cancer treatment.
December 2010. The Medical Subject Heading (MeSH) term "Colorectal Neoplasms" was combined with additional headings or text strings related to patterns of care, such as "physician's practice patterns," "guideline adherence," "chemotherapy," and "radiotherapy" (see Appendix). In total, this search strategy yielded 717 articles.
Articles were hierarchically excluded according to the following criteria: 1) article was an editorial, letter, essay, commentary, conference paper, note, published guideline, highlight, or review; 2) study was based on biological specimens, nonhuman population, simulation model, or hypothetical cohort; 3) study did not report receipt of initial, post-diagnostic surveillance, or end-of-life colorectal cancer care; 4) study reported results from a clinical study or controlled trial evaluating a specific treatment; 5) study included only outcome measures, such as survival; 6) study had sample size of less than 200 cancer patients; and 7) study did not report data for colorectal cancer care separately from other cancer sites.
Data Abstraction
After applying the exclusion criteria to the 717 identified articles, a total of 105 studies were retained and abstracted by four individuals. Additionally, because electronic searches may not include all relevant studies, we reviewed the reference lists of these 105 articles and published reviews of colorectal cancer treatment (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) to identify additional studies for possible inclusion. Through this process, the study team identified 34 additional articles that were also included and abstracted. In total 139 studies were abstracted and a subset of 66 articles reporting patterns of colorectal cancer care in countries outside of North America were included in this systematic review .
The countries represented in this review include Australia, France, Germany, Italy, Spain, the Netherlands, New Zealand, Norway, Sweden, and the United Kingdom. Additionally, one study included in the review compared data from cancer registries in multiple European countries: Genoa and Varese, Italy; Côte-d'Or, France; Granada, Navarra, and Tarragona, Spain; Tampere, Finland; Estonia; Slovenia; Slovakia; and Krakow and Kielce, Poland. The remaining 73 articles were included in the companion review conducted by Butler et al., which examines patterns of colorectal cancer care in the United States and Canada (91) .
A standardized abstraction form was used to record information on study characteristics and principal findings, including initial care and treatment (eg, surgery, radiotherapy [RT] , chemotherapy), post-diagnostic surveillance, and end-of-life care. We also abstracted several study characteristics, including reporting of stage, year of diagnosis or treatment, sample size, patient age, health delivery setting, and data sources. In order to ensure comparability between reviewers, three quality control reviews were conducted and compared for uniformity in abstraction procedures. After each quality control review, adjustments were made to increase consistency in data abstraction. By the last quality review, it was determined that comparability among the four reviewers had been achieved, and studies that were abstracted prior to this point were revisited for secondary abstraction.
Data Analyses
Data are presented for initial care following colorectal cancer diagnosis, post-diagnostic surveillance, and end-of-life care. We abstracted "chemoradiation" or "any adjuvant therapy" as reported in the underlying studies and classified treatment as "multicomponent care" when one particular form of treatment could not be separately abstracted from other treatment types.
Several studies reported multiple types of care, such as rates of surgery as well as chemotherapy. These studies were reported in both tables on surgery and chemotherapy. As a result, some studies may appear in the data tables more than once. Tables presenting studies with findings on receipt of initial care are organized by cancer site and then by year of publication, beginning with the most recent year of publication. Given the limited number of studies focusing on either post-diagnostic surveillance (n = 7) or endof-life care (n = 1), findings from these studies are described in the text only.
Results

Study Characteristics
Out of the total 66 papers included in the review, the vast majority focused on initial treatment for colorectal cancer (Table 1) . Limited research examined either post-diagnostic surveillance or end-of-life care. With respect to distribution by country, the majority of studies were conducted in France (22.7%), the Netherlands (18.2%), the United Kingdom (16.7%), and Australia (12.1%) (Figure 1 ). Categories for components of care were not mutually exclusive. Nearly three-quarters of studies reported rates of surgery (69.7%), whereas approximately half of studies reported rates of radiation treatment (48.5%) and chemotherapy (51.5%).
As shown in Table 2 , the data sources for measuring patterns of care varied significantly in terms of population coverage (eg, single institution vs national) and availability of information about cancer diagnosis, stage at diagnosis, and health services reported. Studies from certain countries, such as France and the Netherlands, relied more heavily on registry data, with several studies using the French network of cancer registries (FRANCIM) or the Eindhoven registry as the data source. By contrast, studies conducted in countries such as Italy, New Zealand, and the United Kingdom relied more heavily on hospital data sources that were comprised of either single or multiple institutions. Studies from other countries had mixed data sources that ranged from national health insurance commissions for pharmaceuticals to single institutions to registries in a particular geographic region or area.
Initial Treatment
Surgery. Forty-six articles included in the review reported rates of surgical treatment and spanned several countries (Table 3) , including France (19.6%), the United Kingdom (19.6%), Australia (15.2%), and the Netherlands (15.2%). Among studies that were not exclusively limited to patients undergoing surgery, rates of resection varied from 54% to 85% (36,57) depending upon cancer site, stage, patient age, disease stage, and study time period. One study was conducted as a European collaboration comparing rates of resection with curative intent across eight European countries (28) and found significant variation of resection rates by country, ranging from 44% in Kielce (Poland) to 86% in Genoa (Italy).
Most studies reported trends in rates of surgery over time and described variation in rates by patient characteristics (ie, age, gender, socioeconomic status, disease severity, comorbidities), hospital setting or volume, and geographical location. Several studies reported increasing or stable rates of surgery for both colon and rectal cancers over time (27, 30, 32, 36, 66, 68, 79) . However, three studies contrasted decreasing trends for abdominoperineal resection (APR) with increasing trends sphincter-sparing surgery (27, 83, 86) . Additionally, a small number of studies compared trends over time to the implementation of guidelines or national consensus statements (32,46,49,52,66,74).
With respect to patient characteristics, several studies found that younger patients were more likely to receive resections (28, 30, 37, 45, 55, 66, 72, 78, 79) . However, other studies indicated mixed findings for rates of surgical treatment by patient age depending upon type of surgery, time period, and disease severity (26, 31, 79) . Studies also reported mixed findings regarding the association of female gender with the likelihood of receiving surgical treatment (31, 38, 55, 84) . Although many studies did not report information on patient socioeconomic status, two UK studies found that patients with lower socioeconomic status were less likely to receive surgical treatment (31, 38) . Additionally, several studies noted that patients * Exceeds 100% because some studies counted in more than one category; percentages for components of care and cancer site were derived by dividing reported number of studies by total number of studies (n = 66); several articles examined both colon and rectal cancers separately; therefore, these studies were counted twice when reporting site of cancer.
with metastatic tumors and comorbidities were often less likely to receive surgical treatment for colorectal cancer (45, 55, 66, 79) . Variation in rates of surgical treatment was also observed by hospital setting and patient volume for several studies. Presentation to the emergency room was associated with a lower likelihood of receiving resections (31, 38, 45, 84) . Hospital type, such as private vs public hospital, was associated with variations in surgical treatment patterns (55, 59, 76) . Additionally, higher hospital volume was associated with lower rates of APR in two studies (42, 85) . A number of studies also highlighted regional variation in rates of surgery for both colon and rectal cancers (57, 63, 69, 79) . Although the majority of studies did not report urban/rural residence, two studies found that individuals living in urban areas were more likely to receive surgery (57, 79) .
Radiation treatment. The majority of the 32 total studies reporting on patterns of RT were conducted in the Netherlands (25.0%), France (21.9%), Australia (12.5%), Norway (9.4%), and the United Kingdom (9.4%) ( Table 4) . Rates of overall RT use varied widely, ranging from 1% to 75% in studies reviewed, depending upon patient age, stage of disease, and study time period (57, 81) . Studies typically reported increasing or stable rates of RT over time; for instance, one study conducted in the Netherlands found a 16% increase over the study period, with 47% receiving RT in 1998-2002 and 63% receiving RT in 2003-2006 (34) . Several studies noted the declining rates of postoperative RT balanced by increasing rates of preoperative RT as a general trend over time (27, 30, 34, 43, 57, 68, 73, 83, 88) . This trend was seen for patients of all age groups, although multiple studies indicated that older patients were less likely to receive either pre-or postoperative RT overall (26, 28, 30, 34, 48, 78, 88) .
Some studies indicated that later stage of diagnosis and tumor status were significant predictors of RT use, with sicker patients being more likely to have RT administered (26, 48, 60, 78, 88) . Two studies found that female patients were less likely to receive preoperative RT (26, 35) . Variation in RT use by hospital setting, hospital volume, and surgery type was also reported by several studies (26, 34, 48, 51, 72, 88) . Lastly, some studies reported regional variation in RT rates (26, 28) .
Chemotherapy. Thirty-four studies reported patterns of chemotherapy use for colorectal cancer, and these were most commonly conducted in France (35.3%), Australia (17.6%), the Netherlands (17.6%), and the United Kingdom (8.8%) ( Table 5) . Overall, chemotherapy use varied substantially between studies, ranging from 0% to 95%, depending upon stage, patient age, and study time period (52, 73) . The single study making national comparisons between European countries found wide variation by cancer registry, ranging from 24% in Krakow to 73% in Slovakia (28) .
Many studies noted increasing trends of chemotherapy use over time, particularly toward the later part of the 1990s (30, 44, 54, 64, 66, 68, 73, 79, 82) . Several studies also indicated that younger patients were more likely to receive chemotherapy compared with older patients, though some highlighted rising rates of chemotherapy use among the elderly over time (28) (29) (30) 40, 46, 47, 60, 61, 66, 68, 69, 78, 79) . Additionally, more advanced tumor stage greatly increased the likelihood of chemotherapy receipt (30, 40, 49, 50, 54, 61, (63) (64) (65) (66) 68, 73, 78, 79) .
Although studies exhibited inconsistent reporting of comorbidities, two studies found that patients with previous malignancies or chronic obstructive pulmonary disease were less likely to receive chemotherapy (60, 61) . Chemotherapy receipt was less likely among both women and patients with lower socioeconomic status in one study (61) . Several studies also highlighted variation in chemotherapy rates by hospital setting (eg, general vs university; private vs public), hospital volume, and emergency room admissions (29, 40, 54, 61, 68, 77) .
Multicomponent care. Out of the 11 studies reporting on patterns of multicomponent care, four were conducted in the Netherlands, three in Germany, and the remaining in Australia, Italy, the United Kingdom, and Norway (Table 6 ). Studies exhibited variation in stage, patient age, and date of diagnosis. Sources of data varied, though data were most commonly from registries (63.6%) (26, 30, 37, 60, 65, 73, 81) . Most studies reported on treatment that combined chemotherapy and radiation, such as chemoradiation or neoadjuvant RT combined with chemotherapy. Predominant findings included higher rates of therapy use over time among younger patients and in higher-volume hospitals (26, 30, 36, 42, 60) .
Post-Diagnostic Surveillance and End-of-Life Care
Seven studies reported information on post-diagnostic surveillance for colorectal cancer, including colonoscopy use, carcinoembryonic antigen testing, chest X-rays, abdominal computed tomography scans or X-rays, and positron emission tomography scans (data not shown) (39, 41, 49, 52, 56, 62, 75) . Five studies reported rates of post-diagnostic surveillance in addition to some form of initial care (eg, surgery, chemotherapy), whereas two studies reported exclusively on post-diagnostic surveillance. Studies varied by timeframe for receipt of follow-up care, ranging from 1 year after diagnosis to 3 years post-diagnosis. Notable findings included that patients with advanced-stage cancers and those receiving chemotherapy were more likely to receive follow-up care (39, 41) . Additionally, variation in post-diagnostic surveillance by physician type (specialist vs general practitioner) and assessment of guideline compliance were also highlighted (39, 41, 62) . The one study conducted in Italy assessing end-of-life care examined patients who died in 2003-2005 and called for guidelines to be created for chemotherapy use among end-of-life patients (data not shown) (43) .
Discussion
This systematic review examined patterns of colorectal cancer care in several European countries, Australia, and New Zealand, and was written as a companion to a review on care patterns in the United States and Canada (91) . Included studies spanned over 15 countries and focused on initial care for colorectal cancer, including surgery, RT, and chemotherapy. Similar to the United States and Canada review, our analysis revealed limited information on post-diagnostic surveillance and end-of-life care for colorectal cancer (91), representing potential areas where additional research is needed (39, 41, 43, 49, 52, 56, 62, 75) . Furthermore, existing studies on end-of-life care have included multiple types of cancer patients, and the extent to which colorectal cancer patients have specific end-of-life care needs is not well understood.
In our analyses of study findings for initial care, there were several findings that were common among studies on surgery, chemotherapy, RT, and multicomponent care. These findings included changing trends over time and variation in rates of treatment by patient demographic and health characteristics (ie, age, gender, socioeconomic status, tumor stage, metastatic tumor status, presence of comorbidities), hospital setting and volume, and region (26, (28) (29) (30) 34, (36) (37) (38) 40, 42, 45, (46) (47) (48) 55, 60, 61, 66, 68, 69, 72, 78, 79, 88) . Among these characteristics, patient age was one of the most consistent findings associated with treatment receipt, with older patients being less likely to receive colorectal cancer care compared with younger patients. This finding may be tied to underrepresentation of elder patients in clinical trials, creating challenges for physicians to determine appropriate treatment for older individuals.
Over time, there were also changing trends in specific treatment types. For example, several studies reported lower rates of APR over time and increasing use of sphincter-sparing surgeries, such as total mesorectal excision and lower anterior resection. This change has particular relevance for quality of life among rectal cancer patients. Several studies also noted increasing use of preoperative RT alongside decreasing rates of postoperative RT among rectal cancer patients. Chemotherapy rates also increased over time, especially toward the later part of the 1990s.
Of critical importance, we found wide variation in data sources used across studies both between and within countries, making direct comparisons of patient and health services information for initial care challenging. Because of lack of comparability of data reporting and differences in patient populations, comparing rates of surgery, RT, or chemotherapy for colorectal cancer between countries was difficult, and patterns of care identified were incongruous. In this review, the studies that were more amenable to comparisons had greater similarities in type of treatment assessed and patient demographic and clinical characteristics (eg, stage III colon cancer patients). These factors should be considered in future research and data collection efforts.
Moreover, studies had multiple sources of data, ranging from registries to single or multiple institutions. Although studies from particular countries such as France and the Netherlands relied heavily on registry data, others used medical records and hospital data or a mixture of data sources. However, there were varied degrees of population coverage and representativeness even within countries using registry data (eg, FRANCIM). Studies from several countries also did not appear to use centralized registry information. Furthermore, increased linkages between health insurance systems and cancer registry data to provide more detailed information on service utilization patterns may improve current data collection efforts.
Studies also had variability in reporting clinical characteristics that significantly affect treatment and survival as well as variation in time period that trends were assessed. Strikingly, 20% of studies did not report stage of cancer at diagnosis-a fundamental determinant of appropriate cancer treatment. Another important clinical characteristic that was omitted from nearly one-third of studies was year of diagnosis. Additionally, assessment of comparability was limited by reporting of treatment rates for initial care from distinct, disparate, and wide intervals of time, ranging from 1974 to 2006, across studies (26, 84) .
Further complicating the ability to make comparisons across countries, few studies assessed care in relation to guidelines or other standards, and those which included this information used disparate guidelines for care receipt. Among the studies that discussed use of guidelines, articles compared trends over time for guideline implementation, but used different sets of guidelines or national consensus conference statements (32, 39, 41, 43, 62, 74) . One study also highlighted better guideline-consistent performance among colorectal cancer surgeons compared with other surgeon types (74) . Although the creation of guidelines is challenging given the diversity of patient populations and physician practice patterns, efforts could potentially be made to improve consistency of treatment with guidelines among stage III colon cancer patients or stages II-III rectal cancer patients where greater consensus exists.
Notably, many studies omitted important patient characteristics, which are associated with receipt of treatment, including comorbidities, gender, socioeconomic status, urban/rural residence, and patient race/ethnicity or country of origin. Several countries included in this review (ie, England, France, Australia, Germany) have significant immigrant populations and racial or ethnic diversity among the general population (92, 93) . In addition, variables related to care coordination (ie, the process of linking patients to timely care throughout the process of treatment), quality of care, case-mix, and social support were missing from nearly all studies. Each of these factors has a potentially important role in treatment receipt and utilization of services, and may vary by patient clinical and demographic characteristics, geographical region, and hospital setting.
It should also be noted that many studies had important limitations. Selection bias and limited geographical coverage were present in several studies. For instance, single-institution studies within a country limit generalizability of findings to other geographical areas. Among studies using registry data, such as those in France, the Netherlands, and Australia, population coverage varied widely both between and within each country.
Although this systematic review made significant efforts to thoroughly evaluate existing literature on patterns of colorectal cancer care, some limitations should be noted. Our search terms and criteria used could have unintentionally resulted in exclusions of relevant studies. However, as an effort to maximize the inclusion of relevant studies, reference lists of identified papers and published reviews were evaluated to identify additional articles. In addition, articles were limited to those published in English, which may have missed relevant studies published in other languages.
These limitations notwithstanding, this review had several important findings and implications. This synthesis of the literature summarizes a large number of studies focusing on colorectal cancer care in Europe, Australia, and New Zealand, and can be used to identify new directions for future research. For instance, one of the primary gaps in existing literature identified by this review was lack of information on post-diagnostic surveillance and end-oflife care among colorectal cancer patients. Another central finding was significant variation in sources of data for colorectal cancer treatment across studies, which varied by patient demographic and health characteristics, study time period, geographic location, and hospital setting. Therefore, future research and policy efforts should minimize inconsistencies in measurement and emphasize standardization of data reporting for colorectal cancer care.
Additional research is also needed that collects and compares standardized data from multiple European nations, such as EUROCARE, which improve data comparability by using similar standards and quality control measures for registration, data collection, and follow-up of patients within cancer registries (3). Researchers and policy makers from individual countries should further work toward increased representativeness and generalizability of data on colorectal cancer treatment between geographical regions within individual nations. Targeted research and policy efforts in these areas will help to harmonize data sources for comparable analyses and allow for improved assessment of care practices globally.
